FENC Fennec Pharmaceuticals Inc.

NASDAQ
$11.62

Fennec Pharmaceuticals Inc. (FENC) is expected to report earnings on February 11, 2027, before the market open. The consensus earnings estimate is $0.15 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +8.3% since its last earnings release on November 12, 2026.

Fennec Pharmaceuticals Beat Consensus Estimates
Thursday, November 12, 2026 · 6:03 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 7:00 AM ET
Earnings Whisper
-
vs $0.15
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $11.35

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly known as Adherex Technologies Inc., is based in United States.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.